"Immunohistochemistry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
| Descriptor ID |
D007150
|
| MeSH Number(s) |
E01.370.225.500.607.512 E01.370.225.750.551.512 E05.200.500.607.512 E05.200.750.551.512 E05.478.583 H01.158.100.656.234.512 H01.158.201.344.512 H01.158.201.486.512 H01.181.122.573.512 H01.181.122.605.512
|
| Concept/Terms |
Immunolabeling Techniques- Immunolabeling Techniques
- Immunolabeling Technique
- Technique, Immunolabeling
- Techniques, Immunolabeling
- Immunolabeling Technics
- Immunolabeling Technic
- Technic, Immunolabeling
- Technics, Immunolabeling
Immunogold Techniques- Immunogold Techniques
- Immunogold Technique
- Technique, Immunogold
- Techniques, Immunogold
- Immunogold Technics
- Immunogold Technic
- Technic, Immunogold
- Technics, Immunogold
Immunogold-Silver Techniques- Immunogold-Silver Techniques
- Immunogold Silver Techniques
- Immunogold-Silver Technique
- Technique, Immunogold-Silver
- Techniques, Immunogold-Silver
- Immunogold-Silver Technics
- Immunogold Silver Technics
- Immunogold-Silver Technic
- Technic, Immunogold-Silver
- Technics, Immunogold-Silver
|
Below are MeSH descriptors whose meaning is more general than "Immunohistochemistry".
Below are MeSH descriptors whose meaning is more specific than "Immunohistochemistry".
This graph shows the total number of publications written about "Immunohistochemistry" by people in this website by year, and whether "Immunohistochemistry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 20 | 20 |
| 1996 | 2 | 23 | 25 |
| 1997 | 0 | 19 | 19 |
| 1998 | 0 | 17 | 17 |
| 1999 | 2 | 33 | 35 |
| 2000 | 0 | 30 | 30 |
| 2001 | 0 | 38 | 38 |
| 2002 | 0 | 50 | 50 |
| 2003 | 0 | 88 | 88 |
| 2004 | 0 | 77 | 77 |
| 2005 | 0 | 80 | 80 |
| 2006 | 1 | 71 | 72 |
| 2007 | 3 | 69 | 72 |
| 2008 | 4 | 76 | 80 |
| 2009 | 1 | 57 | 58 |
| 2010 | 3 | 64 | 67 |
| 2011 | 1 | 66 | 67 |
| 2012 | 2 | 66 | 68 |
| 2013 | 0 | 52 | 52 |
| 2014 | 1 | 56 | 57 |
| 2015 | 2 | 57 | 59 |
| 2016 | 1 | 40 | 41 |
| 2017 | 2 | 36 | 38 |
| 2018 | 5 | 24 | 29 |
| 2019 | 1 | 29 | 30 |
| 2020 | 2 | 15 | 17 |
| 2021 | 2 | 16 | 18 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 2 | 3 |
| 2024 | 0 | 3 | 3 |
| 2025 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunohistochemistry" by people in Profiles.
-
Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses. Breast Cancer Res. 2025 Aug 26; 27(1):154.
-
Impact of NOTCH1 expression in primary breast adenoid cystic carcinoma. J Clin Pathol. 2025 Jul 18; 78(8):548-553.
-
Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
-
Artificial intelligence-based virtual staining platform for identifying tumor-associated macrophages from hematoxylin and eosin-stained images. Eur J Cancer. 2025 May 02; 220:115390.
-
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025 Feb 14; 27(1):22.
-
Nicotinic Acetylcholine Receptor Expression in Merkel Cell Carcinoma Is Associated With Clinical and Histopathologic Parameters. J Cutan Pathol. 2025 Apr; 52(4):317-323.
-
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. J Immunother Cancer. 2025 Jan 08; 13(1).
-
Identification of an early subset of cerebellar nuclei neurons in mice. Elife. 2024 Dec 16; 13.
-
Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genet. 2025 Jan; 290-291:44-50.
-
Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status. J Cutan Pathol. 2025 Mar; 52(3):235-243.